Patents by Inventor Mira Tohmé

Mira Tohmé has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY
    Publication number: 20220233590
    Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
    Type: Application
    Filed: January 7, 2022
    Publication date: July 28, 2022
    Inventors: James Barnaby TRAGER, Luxuan Guo BUREN, Chao GUO, Mira TOHMÉ, Ivan CHAN, Alexandra Leida Liana LAZETIC
  • CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
    Patent number: 11253547
    Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: February 22, 2022
    Assignee: Nkarta, Inc.
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
  • Cancer immunotherapy using CD19-directed chimeric antigen receptors
    Patent number: 11154575
    Abstract: Several embodiments provided for relate to methods of using of anti-CD19 CAR expressing immune cells in immunotherapy. Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: October 26, 2021
    Assignee: Nkarta, Inc.
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
  • Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
    Patent number: 11141436
    Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: October 12, 2021
    Assignee: Nkarta, Inc.
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
  • IMMUNE CELLS ENGINEERED TO EXPRESS CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY
    Publication number: 20210070857
    Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
    Type: Application
    Filed: November 4, 2020
    Publication date: March 11, 2021
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
  • CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY
    Publication number: 20210070856
    Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
    Type: Application
    Filed: November 4, 2020
    Publication date: March 11, 2021
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
  • CANCER IMMUNOTHERAPY USING CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20210060073
    Abstract: Several embodiments provided for relate to methods of using of anti-CD19 CAR expressing immune cells in immunotherapy. Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence.
    Type: Application
    Filed: November 4, 2020
    Publication date: March 4, 2021
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic